Products & Services · Product revenues, net
BRINSUPRI — Product revenues, net
Insmed BRINSUPRI — Product revenues, net increased by 641.0% to $207.85M in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2023
Last reportedQ1 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates successful market penetration, higher patient adoption, or effective commercial execution for the specific product. A decrease may signal competitive pressure, loss of market share, or challenges in patient access and reimbursement.
Detailed definition
This metric represents the total net sales generated from the specific product line or business segment after accounting...
Peer comparison
Comparable to net product sales metrics reported by other biopharmaceutical companies for specific drug franchises or therapeutic segments.
Metric ID:
insm_segment_brinsupri_product_revenues_netHistorical Data
8 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $28.05M | $207.85M |
| QoQ Change | — | — | — | — | — | — | — | +641.0% |
Range$0.00 – $207.85M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Insmed's brinsupri — product revenues, net?
- Insmed (INSM) reported brinsupri — product revenues, net of $207.85M in Q1 2026.
- What does brinsupri — product revenues, net mean?
- The total net sales revenue generated by the BRINSUPRI product segment.